International Stem Cell's Scientists in Collaboration with World Leading Stem Cell Experts Extend Understanding of Human Parthenogenetic Stem Cells in Peer-Reviewed Publications International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com, in collaboration with leading stem cell scientists, announces findings that human parthenogenetic stem cells (hpSC) and human embryonic stem cells (hESC) are similar in their undifferentiated state, and are capable of differentiating into neural lineages such as functional retinal pigment epithelial (RPE) cells that have potential to treat retinal diseases such as age-related macular degeneration. ISCO's CEO Andrey Semechkin, Ph.D., said: "These data are extremely important as they demonstrate that parthenogenetic stem cells have therapeutic potential like conventional embryonic stem cells; however, parthenogenetic stem cells have the additional benefit of superior immune-matching capabilities." This evidence is presented in a recently published paper entitled: "Equivalence of conventionally-derived and parthenote-derived human embryonic stem cells" published in PLoS ONE (Public Library of Science). Hans Keirstead, Ph.D., Professor of Anatomy and Neurobiology and Neurological Surgery at the University of California, Irvine and the senior author of the paper, said: "This work is the first wide-ranging comparison between these two important pluripotent stem cell types and demonstrates that human parthenogenetic stem cells are capable of differentiation along retinal lineages." According to Nikolay Turovets, Ph.D., ISCO's Director of Research and Therapeutic Development and co-author of the paper, "Derivation of RPE from hpSC is the next logical step on the way to developing patient-specific therapies to treat eye degenerative disorders. If studies using RPE derived from hESC demonstrate utility in treating such diseases, it may become necessary to address problems associated with immune rejection. RPE derived from hpSC can be better immune-matched to the patient, thus reducing the chance of immune rejection." This work forms part of ISCO's ophthalmology program developed in collaboration with the team of scientists at the University of California, Irvine led by Dr. H. Keirstead. One of the principal aims of the program is to create three-dimensional retinal tissue for transplantation that may be used to rescue the vision of individuals with retinitis pigmentosa, a group of inherited disorders characterized by progressive vision loss. ISCO has established collaborations with other leading stem cell researchers to exploit the unique qualities of hpSCs. In addition to the collaboration with Keirstead, ISCO scientists co-authored a publication with Jeanne Loring, Ph.D., the Director of the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla, entitled "Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture" published in Cell Stem Cell in January, 2011. Ruslan Semechkin, Ph.D., Vice President of ISCO and co-author on this paper, said: "We are excited about being involved in Dr. Loring's work, which compares molecular characteristics of hundreds of different human pluripotent cell lines." Dr. Loring added: "hpSCs are intriguing because they are pluripotent like hESCs, but have differences in imprinting, the process in embryonic development in which certain genes are inactivated. This makes hpSCs tremendously valuable for understanding the molecular basis of the imprinting process in humans." ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB): International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, www.internationalstemcell.com. To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0. FORWARD-LOOKING STATEMENTS Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements. Key Words: Stem Cells, Biotechnology, Parthenogenesis International Stem Cell Corporation |
Tuesday, January 25, 2011
International Stem Cell's Scientists in Collaboration with World Leading Stem Cell Experts Extend Understanding of Human Parthenogenetic Stem Cells...
Thursday, January 13, 2011
International Stem Cell Corporation Applauds Research Showing Parthenogenesis as a Potential Strategy for Treating Inherited Disease
International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com, applauds a recent announcement by researchers at Nationwide Children's Hospital showing the use of parthenogenetic stem cells as a potential strategy to treat genetic diseases such as Huntington's disease, beta thalassemia or tuberous sclerosis. In a scientific paper entitled, "Gene therapy by allele selection in a mouse model of beta-thalassemia" recently published in the Journal of Clinical Investigation, a team of researchers from the Center for Molecular and Human Genetics (NationwideChildren's Hospital, Columbus, OH), the University of Pennsylvania, the University of North Carolina and the University of Minnesota led by John McLaughlin Ph.D., describe how they used a mouse model of an inherited blood disorder to show that parthenogenesis could be used to create "genetically clean" stem cells. These parthenogenetic stem cells demonstrated the ability to correct certain symptoms of such a disease. Dr. Andrey Semechkin, CEO of ISCO, commented, "We at ISCO are particularly pleased to note this animal model research into the potential of parthenogenetic stem cells since ISCO has created method for creating immortal human parthenogenetic stem cell (hpSC) lines. We are constantly seeking ways to use such technology to treat human diseases, and this announcement is a positive indication showing the potential of parthenogenetic stem cells to treat certain types of autosomal dominant diseases such as particular forms of beta thalassemia or even Huntington's disease. We expect that the transition from animal models to human therapy using parthenogenetic cells will continue to evolve as ISCO continues to conduct its own therapeutic research and to collaborate with researchers across the world to discover new ways to use parthenogenesis and parthenogenetic stem cells to cure human disease. We have great hope that animal research such as that just reported will open new doors to human therapy and look forward to making our human parthenogentic lines available for such therapies." ISCO created and patented the first proven technology to create human parthenogenetic stem cell lines from unfertilized human eggs. This technology has similar potential advantages as those described in the work done at Nationwide Children's Hospital; i.e., the creation of human parthenogenetic stem cells that could eliminate a defective copy of a gene and can be immune-matched to the egg donor. ISCO's technology has the additional ethical advantage of not harming a viable human embryo. Dr Semechkin continues, "ISCO is actively conducting research on the creation and application of differentiated derivatives of hpSC for therapeutic use. Specifically, ISCO has initiated a number of pre-clinical animal studies utilizing both hepatocytes and separately retina pigment epithelium cells, derived from hpSC. ISCO's scientists were also the first to demonstrate the ability of hpSC to differentiate into neural cells and to develop approaches to obtain stable lines of parthenogenetic neural cells. These achievements open up the opportunity to assess the efficacy and safety of using parthenogenetic stem cells as a source to create neural cells for the treatment of diseases such as Parkinson's, Alzheimer's, and other neurodegenerative disorders. The work presented by Dr. McLaughlin once again confirms ISCO's unique position in the field of stem cell based therapies." The work done by Dr. McLaughlin can be found at: http://www.jci.org/articles/view/45377?search%5Barticle_text%5D=&search%5Bauthors_text%5D=mclaughlin. ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB): International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, www.internationalstemcell.com. To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0. FORWARD-LOOKING STATEMENTS Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements. Key Words: Stem Cells, Biotechnology, Parthenogenesis International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Jeffrey Janus, Senior Vice President
760-940-6383
jjanus@intlstemcell.com
Tuesday, January 11, 2011
International Stem Cell Corporation Announces Company Update Conference Call
International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com, announced today that its Chairman, Kenneth Aldrich and the CEO of its Lifeline Skin Care subsidiary, Ruslan Semechkin, PhD, will present a Webinar discussion of the State of the Company and its plans for its Skin Care subsidiary on Wednesday, January 19, 2011 at 10:00 a.m. PST. In announcing the event, Mr. Aldrich stressed that its purpose is not to announce any new programs or financial results, but to attempt to provide an overview of events during the past year and offer shareholders a perspective on what to expect in the coming year. The dial-in number for participants is: 1 (800) 588-4973. Please provide the confirmation number 28808144 to the operator upon calling in. An alternate dial-in number is 1 (847) 230-5643. The confirmation number will be the same for both numbers. A replay of the call will be available on the home page of the company's website at:http://www.internationalstemcell.com. ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB): International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, www.internationalstemcell.com. To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0. Key Words: Stem Cells, Biotechnology, Parthenogenesis International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Ruslan Semechkin, PhD,
Vice President, ISCO, CEO Lifeline Skin Care
ras@intlstemcell.com
